Search Results

You are looking at 1 - 10 of 985 items for :

  • "randomized trials" x
  • Refine by Access: All x
Clear All
Full access

Mark Bloomston, Henry Kaufman, John Winston, Mark Arnold, and Edward Martin

colectomy for colon cancer . N Engl J Med 2004 ; 350 : 2050 – 2059 . 3 Weeks JC Nelson H Gelber S . Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial . JAMA

Full access

Joseph A. Greer, Jamie M. Jacobs, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Molly E. Ream, Emily A. Walsh, Joanne Buzaglo, Alona Muzikansky, Inga T. Lennes, Steven A. Safren, William F. Pirl, and Jennifer S. Temel

real time, ideally enhancing care for patients prescribed oral cancer therapies. We conducted a randomized trial to test the use of a smartphone mobile app to promote adherence to oral therapy for cancer and symptom management. We hypothesized that

Full access

Claudia S.E.W. Schuurhuizen, Annemarie M.J. Braamse, Aartjan T.F. Beekman, Pim Cuijpers, Mecheline H.M. van der Linden, Adriaan W. Hoogendoorn, Hans Berkhof, Dirkje W. Sommeijer, Vera Lustig, Suzan Vrijaldenhoven, Haiko J. Bloemendal, Cees J. van Groeningen, Annette A. van Zweeden, Maurice J.D.L. van der Vorst, Ron Rietbroek, Cathrien S. Tromp-van Driel, Machteld N.W. Wymenga, Peter W. van der Linden, Aart Beeker, Marco B. Polee, Erdogan Batman, Maartje Los, Aart van Bochove, Jan A.C. Brakenhoff, Inge R.H.M. Konings, Henk M.W. Verheul, and Joost Dekker

) to create optimal conditions for a screening and treatment program targeting psychological distress. The goal of this cluster randomized trial (CRT) was to assess the effectiveness of the TES program in improving psychological distress compared with

Full access

Adam L. Cohen and John H. Ward

as an ER agonist in bone and endometrium. 8 It is FDA-approved for the treatment of metastatic breast cancer, the adjuvant treatment of invasive breast cancer and DCIS, and breast cancer risk reduction in high-risk women. Three randomized trials have

Full access

Brittany Bauman, Rosemarie Mick, Eileen Martinez, Theresa M. Lawless, Lindsey Zinck, Paige Sinclair, Mary Fuhrer, Mark O’Hara, Charles J. Schneider, Peter O’Dwyer, John Plastaras, Ursina Teitelbaum, and Kim A. Reiss

during chemotherapy infusion can reduce toxicity to those regions, presumably because of local vasoconstriction. A randomized trial by Nangia et al 6 showed that the application of a “cold cap” during chemotherapy infusion reduced alopecia up to 50% in

Full access

Bishal Gyawali, Elvira D’Andrea, Jessica M. Franklin, and Aaron S. Kesselheim

, physicians, and regulators should be more confident in relying on RRs and DoRs derived from single-arm trials in this context. 3 Some have even argued that for targeted drugs, the need for randomized trials has been eliminated because the durable responses

Full access

Michael Koehler, Susanne Hoppe, Siegfried Kropf, Anke Lux, Rainer Bartsch, Bernhard Holzner, Juergen Krauter, Axel Florschütz, Kathleen Jentsch-Ullrich, Joerg Frommer, Hans-Henning Flechtner, and Thomas Fischer

patients and their caregivers . Psychooncology 2015 ; 24 : 1746 – 1753 . 10.1002/pon.3785 21. Northouse LL , Katapodi MC , Song L , Interventions with family caregivers of cancer patients: meta-analysis of randomized trials . CA Cancer J

Full access

Ashraf Z. Badros

9028 trial. 7 Only one trial, SWOG 9210, has shown a survival benefit with corticosteroid maintenance therapy. 8 In this randomized trial, a prednisone regimen of 50 mg every other day significantly improved median PFS (14 vs. 5 months; P = .003

Full access

Shivan J. Mehta, Sanjay Palat, Catherine Reitz, Evelyn Okorie, Caitlin McDonald, Pamela A. Shaw, Karen Glanz, and David A Asch

to guidelines, but it is not clear how to offer choice through mailed outreach. Insights from behavioral science suggest that opt-out framing may increase participation, while choice overload may reduce uptake. Methods : This is a 3-arm randomized

Full access

Joseph A. Greer, Beverly Moy, Areej El-Jawahri, Vicki A. Jackson, Mihir Kamdar, Juliet Jacobsen, Charlotta Lindvall, Jennifer A. Shin, Simone Rinaldi, Heather A. Carlson, Angela Sousa, Emily R. Gallagher, Zhigang Li, Samantha Moran, Magaret Ruddy, Maya V. Anand, Julia E. Carp, and Jennifer S. Temel

for worse EoL outcomes despite advances in cancer therapies prolonging survival in this population. 2 , 9 , 10 , 20 To address this concern, we conducted a randomized trial of a population-specific PC intervention, which led to higher rates of